CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical tr… Read more
CytoMed Therapeutics Limited Ordinary Shares (GDTC) - Total Assets
Latest total assets as of June 2025: $6.57 Million USD
Based on the latest financial reports, CytoMed Therapeutics Limited Ordinary Shares (GDTC) holds total assets worth $6.57 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
CytoMed Therapeutics Limited Ordinary Shares - Total Assets Trend (2019–2024)
This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
CytoMed Therapeutics Limited Ordinary Shares - Asset Composition Analysis
Current Asset Composition (December 2024)
CytoMed Therapeutics Limited Ordinary Shares's total assets of $6.57 Million consist of 59.6% current assets and 40.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.4% |
| Accounts Receivable | $13.75K | 0.2% |
| Inventory | $614.20K | 8.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $67.87K | 0.9% |
| Goodwill | $259.94 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CytoMed Therapeutics Limited Ordinary Shares's current assets represent 59.6% of total assets in 2024, an increase from 18.7% in 2019.
- Cash Position: Cash and equivalents constituted 49.4% of total assets in 2024, up from 12.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 8.3% of total assets.
CytoMed Therapeutics Limited Ordinary Shares Competitors by Total Assets
Key competitors of CytoMed Therapeutics Limited Ordinary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
CytoMed Therapeutics Limited Ordinary Shares - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - CytoMed Therapeutics Limited Ordinary Shares generates 0.01x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - CytoMed Therapeutics Limited Ordinary Shares is currently not profitable relative to its asset base.
CytoMed Therapeutics Limited Ordinary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.81 | 21.53 | 0.54 |
| Quick Ratio | 5.81 | 19.53 | 0.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.66 Million | $ 5.42 Million | $ -920.28K |
CytoMed Therapeutics Limited Ordinary Shares - Advanced Valuation Insights
This section examines the relationship between CytoMed Therapeutics Limited Ordinary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -21.3% |
| Total Assets | $7.37 Million |
| Market Capitalization | $3.83 Million USD |
Valuation Analysis
Below Book Valuation: The market values CytoMed Therapeutics Limited Ordinary Shares's assets below their book value (0.52 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CytoMed Therapeutics Limited Ordinary Shares's assets decreased by 21.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CytoMed Therapeutics Limited Ordinary Shares (2019–2024)
The table below shows the annual total assets of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $7.37 Million | -21.35% |
| 2023-12-31 | $9.37 Million | +140.17% |
| 2022-12-31 | $3.90 Million | -13.47% |
| 2021-12-31 | $4.51 Million | +56.13% |
| 2020-12-31 | $2.89 Million | +33.21% |
| 2019-12-31 | $2.17 Million | -- |